Clinical trial SASCIA
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2 - negative breast cancer patients with high relapse risk after standard neoadjuvant treatment
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | IBCSG |
| EudraCT Identifier | 2019-004100-35 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04595565 |
| Last update |